The appraisal was discussed by the technology appraisal committee on 9 November 2021. The Committee for Medicinal Products for Human Use (CHMP) has not yet given its opinion on ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma. We are therefore unable to release the committee’s recommendation.